Document Detail


Cathepsin B as a cancer target.
MedLine Citation:
PMID:  23293836     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Cathepsin B is of significant importance to cancer therapy as it is involved in various pathologies and oncogenic processes in humans. Numerous studies have shown that abnormal regulation of cathepsin B overexpression is correlated with invasive and metastatic phenotypes in cancers. Cathepsin B is normally associated with the lysosomes involved in autophagy and immune response, but its aberrant expression has been shown to lead to cancers.
AREAS COVERED: This review highlights the oncogenic role of cathepsin B, discusses the regulation of cathepsin B in light of oncogenesis, discusses the role of cathepsin B as a signaling molecule, and highlights the therapeutic potential of targeting cathepsin B.
EXPERT OPINION: Targeting cathepsin B alone does not appear to abolish tumor growth, and this is probably because cathepsin B appears to have diverse functions and influence numerous pathways. It is not clear whether global suppression of cathepsin B activity or expression would produce unintended effects or cause the activation or suppression of unwanted pathways. A localized approach for targeting the expression of cathepsin B would be more relevant. Moreover, a combination of targeting cathepsin B with other relevant oncogenic molecules has significant therapeutic potential.
Authors:
Christopher S Gondi; Jasti S Rao
Related Documents :
18074906 - Decision making about operability in non-small cell lung cancer.
24323026 - Phase i study of neratinib in combination with temsirolimus in patients with human epid...
16215816 - Dural metastases.
23024836 - Nuclear accumulation of β-catenin and forkhead box o3a in colon cancer: dangerous liai...
10430786 - Determination of the complex between urokinase and its type-1 inhibitor in plasma from ...
3312296 - Reporting colorectal cancer.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2013-01-08
Journal Detail:
Title:  Expert opinion on therapeutic targets     Volume:  17     ISSN:  1744-7631     ISO Abbreviation:  Expert Opin. Ther. Targets     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-13     Completed Date:  2013-07-30     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101127833     Medline TA:  Expert Opin Ther Targets     Country:  England    
Other Details:
Languages:  eng     Pagination:  281-91     Citation Subset:  IM    
Affiliation:
University of Illinois College of Medicine at Peoria, Department of Cancer Biology and Pharmacology and Neurosurgery, Peoria, IL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cathepsin B / antagonists & inhibitors,  metabolism*
Humans
Neoplasms / drug therapy,  metabolism*
Grant Support
ID/Acronym/Agency:
CA 116708/CA/NCI NIH HHS; R01 CA116708/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
EC 3.4.22.1/Cathepsin B
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Examination of the U.S. EPA's vapor intrusion database based on models.
Next Document:  Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogene...